Log in

13 HUTCHMED (China) Limited HKEX · Hong Kong

HUTCHMED (China) (13) news

HUTCHMED (China) Limited is a public biotech or pharmaceutical company listed on HKEX under the ticker 13, recorded under Hong Kong. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest HUTCHMED (China) news

We have not published a story on HUTCHMED (China) yet. When there is news, it will appear here.

What HUTCHMED (China) does

HUTCHMED (China) Limited is a global commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company started in China in 2000 and has built drug discovery, development and commercial operations. Three of its internally developed drugs are commercially available in China: savolitinib, sold as Orpathys, fruquintinib, sold as Elunate in China and as Fruzaqla by its partner Takeda outside China, and surufatinib, sold as Sulanda. Fruzaqla has received approval in 38 countries to date. Savolitinib is partnered globally with AstraZeneca, and fruquintinib is partnered outside China with Takeda, while surufatinib is unpartnered. In addition, the company has 15 other drug candidates in clinical development and several preclinical candidates. Its pipeline covers targets including MET, VEGFR, FGFR, CSF-1R, Syk, EZH2, PI3K/PIKK, IDH, ERK, BTK, CD47, SHP2 and menin. The company also runs a drug marketing and distribution business in China, and it built an in-house oncology sales team of approximately 780 persons at the end of 2025.

Product or programWhat it isStage
Savolitinib (Orpathys)Targeted therapy partnered globally with AstraZenecacommercially available in China
Fruquintinib (Elunate, Fruzaqla)Targeted therapy sold as Elunate in China and as Fruzaqla outside China through Takedacommercially available in China; Fruzaqla approved in 38 countries
Surufatinib (Sulanda)Unpartnered oncology drugcommercially available in China
Other drug candidatesCandidates in clinical development, plus several preclinical candidatesclinical development

Summarised from the company's 20-F filed Mar 5, 2026.

HUTCHMED (China) annual financials

LineFY2025FY2024
Research and development$148.3 million$212.1 million
Net income (loss)$456.9 million$37.7 million
Cash from operations-$64.7 million$497,000
Cash and equivalents$71.3 million$154.0 million
Short-term investments$1.30 billion$682.2 million

Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents $71.3 million, plus short-term investments of $1.30 billion, $1.37 billion in all.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about HUTCHMED (China)

What is the ticker symbol of HUTCHMED (China)?

HUTCHMED (China) Limited trades under the ticker 13 on HKEX.

Where is HUTCHMED (China) listed?

HUTCHMED (China) Limited is listed on HKEX. Our directory also records these other listings: GETTEX:H7T2; LSE:0J7G; LSE:HCM; NASDAQ:HCM.

What is the SEC CIK of HUTCHMED (China)?

The SEC Central Index Key (CIK) for HUTCHMED (China) Limited is 1648257. Its filings are on SEC EDGAR.

How many shares does HUTCHMED (China) have outstanding?

872,327,620 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-05.

Which country or territory is HUTCHMED (China) listed under?

Our directory records HUTCHMED (China) Limited under Hong Kong.

What does HUTCHMED (China) do?

Our directory classifies HUTCHMED (China) Limited as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of HUTCHMED (China)?

The ISIN recorded for HUTCHMED (China) Limited is KYG4672N1198.

Does aibio.space cover HUTCHMED (China)?

aibio.space lists HUTCHMED (China) Limited among 2,820 public biotech companies and publishes its news here as stories appear.

Where is HUTCHMED (China) incorporated?

SEC records list its state or country of incorporation as E9.

What does HUTCHMED (China) develop?

HUTCHMED (China) Limited is a global commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company started in China in 2000 and has built drug discovery, development and commercial operations.

What is Savolitinib (Orpathys) from HUTCHMED (China)?

Savolitinib (Orpathys): Targeted therapy partnered globally with AstraZeneca Stage: commercially available in China.

What is Fruquintinib (Elunate, Fruzaqla) from HUTCHMED (China)?

Fruquintinib (Elunate, Fruzaqla): Targeted therapy sold as Elunate in China and as Fruzaqla outside China through Takeda Stage: commercially available in China; Fruzaqla approved in 38 countries.

Is HUTCHMED (China) profitable?

HUTCHMED (China) Limited reported net income of $456.9 million for the fiscal year ended Dec 31, 2025, and used $64.7 million of cash in operations, per its annual report to the SEC.

How much does HUTCHMED (China) spend on research and development?

$148.3 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does HUTCHMED (China) have?

$1.37 billion in cash and short-term investments at Dec 31, 2025, per its 20-F.

Investor discussion: HUTCHMED (China)

Members talk about HUTCHMED (China) (13). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at HUTCHMED (China), newest first. Each line links the filing it comes from.

  1. Mergers

    Transaction under the Listing Rules: Extraordinary General Meeting held on March 31, 2025 - Poll Results. Source

  2. Mergers

    Transaction under the Listing Rules: MAJOR TRANSACTION IN RELATION TO THE DISPOSAL OF A TOTAL OF 45% EQUITY INTEREST IN SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED AND NOTICE OF EXTRAORDINARY GENERAL MEETING. Source

  3. Mergers

    Transaction under the Listing Rules: MAJOR TRANSACTION IN RELATION TO THE DISPOSAL OF 45% EQUITY INTEREST IN SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED - DESIGNATION OF PURCHASERS. Source

  4. Mergers

    Transaction under the Listing Rules: MAJOR TRANSACTION IN RELATION TO THE DISPOSAL OF 45% EQUITY INTEREST IN SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED - TIMING OF DISPATCH OF CIRCULAR. Source

  5. Mergers

    Transaction under the Listing Rules: MAJOR TRANSACTION IN RELATION TO THE DISPOSAL OF 45% EQUITY INTEREST IN SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED - TIMING OF DISPATCH OF CIRCULAR. Source

  6. Mergers

    Transaction under the Listing Rules: MAJOR TRANSACTION IN RELATION TO THE DISPOSAL OF 45% EQUITY INTEREST IN SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED. Source

Press releases

Headlines of HUTCHMED (China)'s own announcements, newest first. Each opens the full release on the newswire that carried it.

  1. HKEXnews

    VOLUNTARY ANNOUNCEMENT - Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer

  2. HKEXnews

    VOLUNTARY ANNOUNCEMENT - HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS plus TAGRISSO in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026

  3. HKEXnews

    VOLUNTARY ANNOUNCEMENT - HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine

  4. HKEXnews

    VOLUNTARY ANNOUNCEMENT - HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China

  5. HKEXnews

    VOLUNTARY ANNOUNCEMENT - HUTCHMED Announces Submission of US NDA for ORPATHYS plus TAGRISSO in MET Driven EGFR-Mutated Lung Cancer

  6. HKEXnews

    VOLUNTARY ANNOUNCEMENT - HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors

  7. HKEXnews

    VOLUNTARY ANNOUNCEMENT - HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026

  8. HKEXnews

    HUTCHMED ANNOUNCES LICENSING AGREEMENT WITH GSK FOR KRAS-EGFR-ANTIBODY CONJUGATE CANCER THERAPY

  9. HKEXnews

    HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS Plus TAGRISSO in Treatment-Naive Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China

  10. HKEXnews

    VOLUNTARY ANNOUNCEMENT - HUTCHMED Announces NMPA Approval for ATLED (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma

  11. HKEXnews

    ANNOUNCEMENT PURSUANT TO RULES 13.51B(2) AND 13.51(2)(l) OF THE LISTING RULES

  12. HKEXnews

    HUTCHMED Announces ORPATHYS Plus TAGRISSO Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO

  13. HKEXnews

    Notification letter to non-registered shareholders and reply form: Notice of Publication of the 2026 Interim Report

  14. HKEXnews

    Notification letter to registered shareholders and reply form: Notice of Publication of the 2026 Interim Report

  15. HKEXnews

    HUTCHMED Reports 2026 Interim Results

  16. HKEXnews

    VOLUNTARY ANNOUNCEMENT - HUTCHMED Announces NMPA Approval for ORPATHYS for the treatment of Gastric Cancer Patients with MET Amplification

  17. HKEXnews

    Blocklisting Six Monthly Return

  18. HKEXnews

    VOLUNTARY ANNOUNCEMENT - HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026

  19. HKEXnews

    VOLUNTARY ANNOUNCEMENT - HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress

  20. HKEXnews

    Block Admission Application

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:13 on TradingView.

SEC filings and registration

SEC name
HUTCHMED (China) Ltd
CIK
1648257
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
HCM (Nasdaq), HMDCF (OTC)
State or country of incorporation
E9
Filer category
Large accelerated filer
Business address
48TH FLOOR, CHEUNG KONG CENTER, HONG KONG
Phone
852-2121-3888
Shares outstanding
872,327,620 as of 2025-12-31 (20-F filed 2026-03-05)
Former names
Hutchison China MediTech Ltd

Recent filings (8-K and 6-K are the company's own announcements)

  • 6-K filed 2026-10-21
  • 6-K filed 2026-09-29
  • 6-K filed 2026-09-29
  • 6-K filed 2026-09-24
  • 6-K filed 2026-09-03
  • 6-K filed 2026-08-31
  • 6-K filed 2026-08-28
  • 6-K filed 2026-08-18

Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Listing details

HUTCHMED (China) Limited is a public biotech or pharmaceutical company listed on HKEX under the ticker 13, recorded under Hong Kong. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
HUTCHMED (China) Limited
Ticker
13
Listing
HKEX
Country or territory
Hong Kong
Business scope
Pharmaceuticals: Major
ISIN
KYG4672N1198
Other listed symbols
GETTEX:H7T2; LSE:0J7G; LSE:HCM; NASDAQ:HCM
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.